title: Conjugated estrogen/bazedoxifene tablets for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.
abstract: Conjugated estrogen/bazedoxifene (CE/BZA) therapy represents a new, progestin-free treatment in the management of postmenopausal health. CE/BZA pairs CE with the selective estrogen receptor modulator, BZA. The rationale for the development of CE/BZA was that BZA, acting primarily as a selective estrogen receptor degrader in uterine and breast tissue, would sufficiently inhibit the proliferative effects of CE on the endometrium. The absence of a progestin would reduce the incidence of uterine bleeding, breast pain and increased breast density associated with progestin-containing hormone therapy. CE/BZA has been evaluated in five multicenter, randomized, double-blind, placebo-controlled, and active-controlled Phase III trials known as the SMART trials. CE/BZA has been shown to maintain the established benefits of estrogen therapy for treatment of vasomotor symptoms and prevention of a loss in bone mineral density (bone mass), while minimizing certain estrogenic effects, particularly in the uterine endometrium and breast.
authors.affiliation: Pfizer Inc., 500 Arcola Rd, Room B-4207, Collegeville, PA 19426, USA.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Mirkin
authors.forename: Barry
authors.initials: B
authors.lastname: Komm
authors.forename: James H
authors.initials: JH
authors.lastname: Pickar
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D004967:Estrogens / Q000627:therapeutic use*; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use*; D005260:Female; D019584:Hot Flashes / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008875:Middle Aged; D017698:Postmenopause / Q000502:physiology*; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013546:Sweating / Q000502:physiology*; D016896:Treatment Outcome; D014666:Vasomotor System / Q000503:physiopathology*
chemical_list: D050071:Bone Density Conservation Agents; D004338:Drug Combinations; D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D007211:Indoles; D020845:Selective Estrogen Receptor Modulators; C447119:bazedoxifene